Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
News Medical

Study concludes a single intramuscular injection of adintrevimab provides prophylactic efficacy against COVID-19 without safety concerns

In a recent study published in Open Forum Infectious Diseases, researchers evaluated the prophylactic immune protection conferred by a single intramuscular (I.M.) injection of adintrevimab (ADG20) ...